In summary, in this observational study of everyday clinical practice, we have shown here for the first time that once daily insulin glargine plus OADs is an effective therapeutic regimen with a good safety profile for patients with T2DM who were inadequately controlled with premixed insulin. The gene discussed is INS; the disease is type 2 diabetes mellitus.